Cardiac DNA InsightSM

Cardiac DNA InsightSM can help identify a patient’s propensity for increased risk of certain heart-related health conditions. This report also examines eight classes of drugs that affect the cardiovascular system: anti-platelets, anti-coagulants, statins, stimulants, beta-blockers, ACE inhibitors, calcium channel blockers and hormone therapies. Cardiac DNA Insight may be used to enhance the information provided in lipid tests that evaluate risk for cardiovascular disease.

Cardiac DNA InsightSM provides information that allows the physician to:

  • Better monitor a patient’s specific health condition.
  • Prescribe a more optimal medication and dosage for a patient.
  • Suggest early lifestyle and diet interventions to help combat or prevent certain health conditions.

Cardiac DNA Insight analyzes a patient’s unique genetic markers, which influence a broad range of heart-related conditions, including ApoE, HDL and LDL cholesterol levels, and risks for hypertension and myocardial infarction. This simple saliva-based test is supported by scientifically validated genetic testing technologies using clinically relevant markers and assays.

Pathway Genomics provides physicians and patients access to a genetic counselor at no charge to review individual results.

The Cardiac DNA InsightSM genetic test reports on the following conditions and traits:

Heart Disease/ Atrial Fibrillation
Atrial fibrillation
Beta-blockers, LVEF response
Caffeine metabolism
Coronary artery disease
Myocardial infarction
Simvastatin-induced myopathy
Verapamil and QTc interval
Peripheral Arterial Disease/ Venous Thrombosis
Clopidogrel metabolism (Plavix)
Estrogen supplementation (risk of venous thrombosis)
Peripheral arterial disease
Venous thrombosis
Metoprolol metabolism
Perindopril (ACE inhibitor-therapeutic benefit)
Verapamil vs. atenolol (benefit of)
Cardiovascular Health
ApoE and cardiovascular disease
Genetic risk for decreased folate
Genetic risk for decreased HDL cholesterol
Genetic risk for elevated LDL cholesterol
Genetic risk for elevated triglycerides
Sickle cell anemia
back to top